Maxim Group Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Buy

Maxim Group upgraded shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) from a hold rating to a buy rating in a report issued on Monday, MarketBeat reports. Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, July 19th. They set a sell rating on the stock. Galmed Pharmaceuticals Stock […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Millennium Management ,Galmed Pharmaceuticals Stock Performance ,Raymond James Financial Services Advisors Inc ,Galmed Pharmaceuticals Ltd ,Galmed Pharmaceuticals ,Cambridge Investment Research Advisors Inc ,Galmed Pharmaceuticals Company Profile ,Hedge Funds Weigh In On Galmed Pharmaceuticals ,Maxim Group ,News Ratings For Galmed Pharmaceuticals Daily ,Free Report ,Get Free Report ,Investment Research Advisors ,Raymond James Financial Services Advisors ,James Financial Services Advisors ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Upgrade ,